Figure 2
From: Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
neoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study design. CTCs, circulating tumour cells; FEC, 5-fluoruracil-epirubicin-cyclophosphamide; PET, positron emission tomography. Note: In the combined Lapatinib + Trastuzumab + Paclitaxel arm, there is a protocol amendment pending approval to reduce the Lapatinib dose to 750 mg/day because of concerns regarding excess diarrhea. Reprinted with permission from GlaxoSmithKline and SOLTI (Spanish Breast Cancer Cooperative Group).